Pharmaceuticals

Acquired Autoimmune Hemolytic Anemia Market Size Forecast: Revenue and CAGR by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Acquired Autoimmune Hemolytic Anemia Industry By The Forecast Year 2029?

The market for acquired autoimmune hemolytic anemia has demonstrated robust expansion over the past few years. Projections indicate its size will expand from $2.01 billion in 2024 to $2.14 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.5%. This historical growth is linked to factors such as increasing diagnosis rates, the rising incidence of secondary AIHA, the expansion of hospital hematology units, government and regulatory support, and increased investment in hematology.

The market for acquired autoimmune hemolytic anemia is anticipated to experience substantial growth in the coming years. It is forecast to grow to “$2.81 billion in 2029, achieving a compound annual growth rate (CAGR) of 7.1%. This expansion during the projection period can be attributed to the rising prevalence of autoimmune diseases, a deeper understanding of the complement system’s function, increased partnerships between biopharma and academic institutions, the growing implementation of personalized medicine, and the expanding elderly demographic. Prominent trends expected in the forecast period include the integration of targeted biologic therapies, advancements in complement pathway inhibitors, the use of AI and data analytics in disease management, AI-driven clinical trial design, and innovations in orphan drugs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp

Which Drivers Are Impacting The Acquired Autoimmune Hemolytic Anemia Market?

The future expansion of the acquired autoimmune hemolytic anemia market is projected to be propelled by the increasing occurrence of autoimmune disorders. Autoimmune disorders are characterized by the immune system erroneously targeting the body’s own healthy cells and tissues, mistaking them for dangerous invaders. The rising prevalence of these disorders is largely attributed to a surge in environmental triggers and changes in lifestyle that can disrupt immune system regulation. This increased prevalence of autoimmune disorders contributes to a higher incidence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more susceptible to developing secondary AIHA due to immune system dysregulation. For instance, in 2022, according to the autoimmune registry, a US-based organization specializing in gathering and evaluating information about autoimmune disorders, the proportion of patients diagnosed with multiple autoimmune conditions rose from 52% in 2021 to 55% in 2022. Therefore, the expanding prevalence of autoimmune disorders will drive the growth of the acquired autoimmune hemolytic anemia market.

What Are The Emerging Segments Gaining Attention In The Acquired Autoimmune Hemolytic Anemia Market?

The acquired autoimmune hemolytic anemia market covered in this report is segmented –

1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test

2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab

3) By Severity: Mild, Moderate, Severe

4) By End User: Hospitals, Specialty Clinics, Research Institutions

Subsegments:

1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count

2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count

3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test

4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing

How Are Emerging Market Trends Shaping The Acquired Autoimmune Hemolytic Anemia Industry Landscape?

Leading companies within the acquired autoimmune hemolytic anemia market are prioritizing developments in targeted therapeutic approaches, specifically humanized monoclonal antibodies, aiming to enhance treatment effectiveness, mitigate adverse reactions, and offer more tailored care solutions for individuals afflicted with autoimmune hemolytic anemia. A humanized monoclonal antibody, a protein engineered in laboratories, is crafted to replicate human antibodies, possessing a predominantly human structure yet incorporating minor non-human (typically mouse) antibody segments to bolster its capacity to precisely target particular antigens and reduce the likelihood of immune system rejection. Illustratively, in February 2022, Sanofi, a healthcare company based in France, secured approval from the U.S. Food and Drug Administration (FDA), a US-based government agency, for Enjaymo (sutimlimab-jome), marking it as the initial and sole therapy for cold agglutinin disease (CAD), which is a rare form of autoimmune hemolytic anemia. This treatment functions by specifically inhibiting C1s within the classical complement pathway, thereby preventing the immune system from assaulting and eradicating healthy red blood cells and consequently diminishing the requirement for red blood cell transfusions among CAD patients. Enjaymo specifically targets C1-activated hemolysis, leaving the lectin or alternative complement pathways unaffected.

Who Are The Major Companies Operating In The Acquired Autoimmune Hemolytic Anemia Market?

Major companies operating in the acquired autoimmune hemolytic anemia market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Rakshit Drugs Private Limited, Aarti Pharmalabs Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/acquired-autoimmune-hemolytic-anemia-global-market-report

Which Regional Markets Are Contributing Most To The Acquired Autoimmune Hemolytic Anemia Industry Expansion?

North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Acquired Autoimmune Hemolytic Anemia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24132&type=smp

Browse Through More Reports Similar to the Global Acquired Autoimmune Hemolytic Anemia Market 2025, By The Business Research Company

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795